108 related articles for article (PubMed ID: 25600566)
1. Different adjuvant chemotherapy regimens in older breast cancer patients?
Wildiers H; Brain E
Ann Oncol; 2015 Apr; 26(4):613-615. PubMed ID: 25600566
[No Abstract] [Full Text] [Related]
2. Upfront adjuvant aromatase inhibitors in women with lobular breast cancer.
Montemurro F
Eur J Cancer; 2013 Oct; 49(15):3376-7. PubMed ID: 23867125
[No Abstract] [Full Text] [Related]
3. De-escalation attempts for adjuvant trastuzumab: longer beats shorter.
Curigliano G; Goldhirsch A
Ann Oncol; 2015 Jul; 26(7):1275-6. PubMed ID: 26002609
[No Abstract] [Full Text] [Related]
4. Inhibiting angiogenesis in breast cancer: the beginning of the end or the end of the beginning?
Rugo HS
J Clin Oncol; 2012 Mar; 30(9):898-901. PubMed ID: 22331930
[No Abstract] [Full Text] [Related]
5. Different outcome variables yield different results!
Brouckaert O; Wildiers H; Neven P
Ann Oncol; 2013 Feb; 24(2):554. PubMed ID: 23277485
[No Abstract] [Full Text] [Related]
6. Letter to the editor - author's response.
van de Water W; Fontein DB; van de Velde CJ
Eur J Cancer; 2013 Oct; 49(15):3378-9. PubMed ID: 23890770
[No Abstract] [Full Text] [Related]
7. Reply to 'Different outcome variables yield different results', by O. Brouckaert et al.
Truin W; Voogd AC; Roumen RMH
Ann Oncol; 2013 Feb; 24(2):555. PubMed ID: 23341480
[No Abstract] [Full Text] [Related]
8. [Response evaluation with mammography and ultrasound].
Junkermann H; Schmid H; Sinn HP; Wallwiener D
Zentralbl Gynakol; 1996; 118(10):572-3. PubMed ID: 8999712
[No Abstract] [Full Text] [Related]
9. Hand-foot syndrome in breast cancer patients receiving adjuvant chemotherapy.
Lee CK; Lynch J
Intern Med J; 2007 Apr; 37(4):281-2. PubMed ID: 17388876
[No Abstract] [Full Text] [Related]
10. Inflammatory breast cancer after neoadjuvant chemotherapy: can magnetic resonance imaging precisely diagnose the final pathological response?
Chen JH; Mehta RS; Nalcioglu O; Su MY
Ann Surg Oncol; 2008 Dec; 15(12):3609-13. PubMed ID: 18807091
[No Abstract] [Full Text] [Related]
11. Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer - a TEAM study analysis.
van de Water W; Fontein DB; van Nes JG; Bartlett JM; Hille ET; Putter H; Robson T; Liefers GJ; Roumen RM; Seynaeve C; Dirix LY; Paridaens R; Kranenbarg EM; Nortier JW; van de Velde CJ
Eur J Cancer; 2013 Jan; 49(2):297-304. PubMed ID: 22954666
[TBL] [Abstract][Full Text] [Related]
12. German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer.
von Minckwitz G; Möbus V; Schneeweiss A; Huober J; Thomssen C; Untch M; Jackisch C; Diel IJ; Elling D; Conrad B; Kreienberg R; Müller V; Lück HJ; Bauerfeind I; Clemens M; Schmidt M; Noeding S; Forstbauer H; Barinoff J; Belau A; Nekljudova V; Harbeck N; Loibl S
J Clin Oncol; 2013 Oct; 31(28):3531-9. PubMed ID: 23980081
[TBL] [Abstract][Full Text] [Related]
13. Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma.
Cocquyt VF; Blondeel PN; Depypere HT; Praet MM; Schelfhout VR; Silva OE; Hurley J; Serreyn RF; Daems KK; Van Belle SJ
Eur J Surg Oncol; 2003 May; 29(4):361-7. PubMed ID: 12711290
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant chemotherapy for elderly patients (> or =70 years) with early high-risk breast cancer: a retrospective analysis of 260 patients.
Brunello A; Basso U; Pogliani C; Jirillo A; Ghiotto C; Koussis H; Lumachi F; Iacobone M; Vamvakas L; Monfardini S
Ann Oncol; 2005 Aug; 16(8):1276-82. PubMed ID: 15919685
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil as adjuvant chemotherapy in breast cancer.
Livi L; Saieva C; Borghesi S; De Luca Cardillo C; Scotti V; Mangoni M; Greto D; Cataliotti L; Paiar F; Bianchi S; Biti GP
J Chemother; 2009 Nov; 21(5):558-65. PubMed ID: 19933048
[TBL] [Abstract][Full Text] [Related]
16. Goserelin plus tamoxifen compared to chemotherapy followed by tamoxifen in premenopausal patients with early stage-, lymph node-negative breast cancer of luminal A subtype.
Alramadhan M; Ryu JM; Rayzah M; Nam SJ; Kim SW; Yu J; Lee SK; Bae SY; Park S; Paik HJ; Lee JE
Breast; 2016 Dec; 30():111-117. PubMed ID: 27697675
[TBL] [Abstract][Full Text] [Related]
17. Febrile neutropaenia and chemotherapy discontinuation in women aged 70 years or older receiving adjuvant chemotherapy for early breast cancer.
Adjogatse D; Thanopoulou E; Okines A; Thillai K; Tasker F; Johnston SR; Harper-Wynne C; Torrisi E; Ring A
Clin Oncol (R Coll Radiol); 2014 Nov; 26(11):692-6. PubMed ID: 24909701
[TBL] [Abstract][Full Text] [Related]
18. TYMS, MTHFR, p53 and MDR1 gene polymorphisms in breast cancer patients treated with adjuvant therapy.
Henríquez-Hernández LA; Pérez LF; Hernández AG; de León AC; Díaz-Chico B; Rosales AM
Cancer Epidemiol; 2010 Aug; 34(4):490-3. PubMed ID: 20371218
[TBL] [Abstract][Full Text] [Related]
19. Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: a retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy.
Bozovic-Spasojevic I; Ameye L; Paesmans M; Larsimont D; Di Leo A; Dolci S; Piccart M; de Azambuja E; Loi S
Breast; 2014 Aug; 23(4):473-81. PubMed ID: 24768477
[TBL] [Abstract][Full Text] [Related]
20. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
